A detailed history of Envestnet Asset Management Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 21,141 shares of DNLI stock, worth $567,635. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,141
Previous 22,296 5.18%
Holding current value
$567,635
Previous $457,000 7.22%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$14.96 - $23.22 $17,278 - $26,819
-1,155 Reduced 5.18%
21,141 $490,000
Q1 2024

May 13, 2024

SELL
$15.83 - $23.35 $20,024 - $29,537
-1,265 Reduced 5.37%
22,296 $457,000
Q4 2023

Feb 13, 2024

BUY
$16.2 - $23.18 $7,128 - $10,199
440 Added 1.9%
23,561 $505,000
Q3 2023

Nov 13, 2023

BUY
$20.63 - $30.17 $154,683 - $226,214
7,498 Added 47.99%
23,121 $476,000
Q2 2023

Aug 04, 2023

SELL
$23.37 - $32.96 $603,273 - $850,829
-25,814 Reduced 62.3%
15,623 $461,000
Q1 2023

May 11, 2023

BUY
$21.91 - $32.67 $11,393 - $16,988
520 Added 1.27%
41,437 $954,000
Q4 2022

Feb 07, 2023

SELL
$26.28 - $33.92 $15,741 - $20,318
-599 Reduced 1.44%
40,917 $1.14 Million
Q3 2022

Nov 10, 2022

BUY
$25.97 - $38.53 $287,565 - $426,642
11,073 Added 36.37%
41,516 $1.27 Million
Q2 2022

Aug 03, 2022

SELL
$20.88 - $35.19 $60,865 - $102,578
-2,915 Reduced 8.74%
30,443 $896,000
Q1 2022

May 04, 2022

BUY
$29.0 - $47.27 $139,055 - $226,659
4,795 Added 16.79%
33,358 $1.07 Million
Q4 2021

Feb 04, 2022

BUY
$42.59 - $55.02 $98,468 - $127,206
2,312 Added 8.81%
28,563 $1.27 Million
Q3 2021

Oct 07, 2021

BUY
$48.48 - $78.23 $1.27 Million - $2.05 Million
26,251 New
26,251 $1.32 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.6B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.